Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
4 evidence topics · 11 sources
Summary: limitations of current therapies
No therapy directed at APOL1-mediated kidney disease is approved; the KDIGO 2025 conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”, and a 2021 Delphi consensus agreed that “No specific treatment is currently available”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, the primary kidney outcome occurred in 58.1% of participants with a high-risk genotype and 36.6% of those with a low-risk genotype (hazard ratio 1.88), with no interaction between APOL1 status and the randomized blood-pressure goal or antihypertensive drug. In the FSGS Clinical Trial, APOL1 genotype did not affect proteinuria response to cyclosporine or mycophenolate mofetil with dexamethasone, but participants with the high-risk genotype were more likely to progress to ESRD. In DUPLEX, sparsentan reduced proteinuria more than irbesartan without a significant difference in eGFR slope at 108 weeks, and the APOL1 high-risk subgroup comprised 14 participants. In a real-world cohort of 1,332 people with AMKD, 35.7% had a RAAS inhibitor fill or administration and 10.5% an SGLT2 inhibitor, and 45.7% had CKD stage 4 or 5.
No approved disease-directed therapy
“There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A24. No specific treatment is currently available for patients with APOL1-associated nephropathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is currently no specific treatment or management protocol for APOL1-associated nephropathy, and so, the clinical value of APOL1 testing in routine clinical practice has not been established.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression despite blood pressure control and RAS inhibition
“In conclusion, renal high-risk variants in APOL1 were associated with an increased risk of progression of chronic kidney disease among black patients, even among those with well-controlled blood pressure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, therapeutic options to retard disease progression are limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote